| Oct 9 |
Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price
|
| Oct 9 |
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
|
| Oct 8 |
Arcus a new overweight at Wells Fargo on potential of casdatifan in kidney cancer
|
| Oct 2 |
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
|
| Sep 23 |
Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones
|
| Sep 13 |
Arcus up 4% following Merck Welireg kidney cancer data
|
| Sep 10 |
Arcus Biosciences Announces New Employment Inducement Grants
|
| Aug 28 |
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m
|
| Aug 27 |
Arcus Biosciences secures $250M term loan facility
|
| Aug 27 |
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
|
